Synairgen data analysis provides 'strong clinical rationale' to continue work on Covid treatment
A review of phase III data has identified a group of virus sufferers that could potentially benefit from SNG001
Company
Synairgen PLC
LON:SNG
Synairgen PLC is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections.
149 stories · page 2 of 8
Synairgen to present data from phase III Covid trial at leading industry conference
It has been selected for two sessions at the ATS 2022 gathering in San Francisco next month
Synairgen says there are 'ongoing discussions' to find new trial for lead asset after US study is halted
The ACTIV-2 evaluation was halted following the “significant shift in the nature of the pandemic"
Synairgen updates on SNG001
It provided guidance on work being carried out by the US National Institutes of Health and shared lab results that revealed "potent antiviral activity” against Delta and Omicron of its lead asset
Synairgen phase III results disappoint
“[The] improvement in patient care may have compromised the potential of SNG001 to show a clinical benefit in respect of the endpoints for this study, which were not met," said chief executive Richard Marsden
Synairgen ties up with Ashfield Engage as it advances Covid-19 treatment
"We are excited to be working with Ashfield Engage given their relevant COVID-19 experience and are confident they understand our needs and values as we build the optimal team," said
Synairgen presents data on antiviral activity of lead asset
The updates were given to the European Scientific Working Group in Influenza conference
Synairgen shares rise 7% after clinical trial update
The shares are still some way shy of finnCap's valuation
Synairgen recruits all 610 patients for final stage trial on COVID-19 drug
The trial has been granted Fast Track status from the US Food and Drug Administration and was classified as an Urgent Public Health study by the UK's National Institute for Health Research
Synairgen COVID-19 treatment gets green light for US government-sponsored Phase III trials
The ACTIV-2 trial tests the treatment in non-hospitalised adults experiencing mild to moderate COVID-19 and is sponsored by the US NIAID
Synairgen appoints chief regulatory officer in preparation for SNG001 regulatory submissions
"His experience and expertise in global regulatory strategy will be invaluable," said chief executive Richard Marsden
Synairgen says COVID-19 treatment trials going well; expects top line results early next year
The drug is seen as having potential value not only for hospitalised COVID-19 patients, but also for other severe viral lung infections caused by cold and flu viruses, and for government stockpiling to prepare for future potential pandemics
Archive
Small cap movers:Synairgen soars after encouraging COVID-related lab tests while the tide turns for SIMEC Atlantis
A look at some of the week's big movers in the small cap world
Synairgen says COVID treatment has shown potent antiviral activity against two variants
"In vitro” experiments were carried out to assess the drug’s potential efficacy against the Kent and South African mutations
Synairgen hails exceptional progress over 2020 towards treatment for COVID-19
The company said a Phase III trial of its SNG001 candidate was initiated last year with the results expected in the second half of 2021
Synairgen price target maintained at 505p by broker finnCap
Treatment led to a threefold likelihood of recovering
Synairgen phase II data points to potential of its drug in severe Covid
Chief executive Richard Marsden said of the read-out: “It increases our conviction in the approach we have taken to conduct an international phase III trial in hospitalised patients requiring supplemental oxygen, which is scheduled to read
Synairgen says US government phase II/III trial of inhaled COVID-19 treatment has begun dosing
The sub-study will evaluate drug SNG001’s potential in people with mild to moderate COVID-19 symptoms not yet requiring hospitalisation
Archive
Maintel holds the line despite the second lockdown
A look at some of the major movers in London on Monday
Synairgen says inhaled drug included in a major US government-sponsored coronavirus trial
The drug discovery and development specialist said researchers will assess SNG001’s potential to help patients not yet requiring hospitalisation